NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Genomic Medicine > Partnership with Danaher paves way for precision medicine test for sepsis 

Partnership with Danaher paves way for precision medicine test for sepsis 

7 November 2023 · Listed under Genomic Medicine

The University of Oxford today announced a partnership with Danaher Corporation to develop a new test to enable precision medicine care for sepsis, a pathological immune response to infection that accounts for one in five deaths globally each year.

generic image of hospital beds
Shutterstock.com

The test will build on research from the laboratory of Julian Knight, a professor of genomic medicine at Oxford and leading expert in sepsis biology. The novel test will leverage rapid molecular diagnostic technologies provided by Cepheid, a Danaher subsidiary, to pinpoint different subtypes of sepsis and allow the development of novel personalised care paths including which targeted therapies are most likely to help. 

Sepsis is a serious condition that occurs when the immune system fails to react normally to an infection and damages tissues throughout the body. If left unchecked, it can lead to complete organ failure.

Currently, doctors cannot accurately predict which patients are most likely to develop sepsis after an infection, nor can they determine which early-stage cases of sepsis are most likely to become severe or life-threatening, and by what mechanisms of immune dysfunction.

However, recent research by the Knight group has shown how molecular approaches based on measuring RNA from white blood cells can identify a specific immune response associated with poor outcome that could benefit from drug intervention.

Being able to subtype sepsis in patients at the molecular level could have many potential clinical benefits, such as enabling doctors to choose suitable therapies and treatment settings. It could also help pharmaceutical companies choose appropriate patients for clinical trials of new or previously developed therapies.

Julian Knight, Professor of Genomic Medicine at the University of Oxford’s Nuffield Department of Medicine, said: “We are delighted to be partnering on this innovative project. We believe this will accelerate progress to a precision medicine approach for sepsis in which we can rapidly identify and treat patients with a particular sepsis response state. We hope the test will help clinicians to choose the right therapy, maximising benefit and minimising harm for the individual patient.

“In our research, we have used a molecular approach to try to understand if there are particular sub-groups of patients that might benefit from specific interventions. We now have a way of measuring the expression of a small number of genes, which allows us to estimate the likelihood of a worse outcome – a sepsis response signature.”

Julian Knight

Professor Knight (pictured left), whose work is supported by the NIHR Oxford Biomedical Research Centre (BRC), whose Genomic Medicine Theme he leads, added: “Current methods – using RNA sequencing and other gene expression measurements – take days or even weeks to carry out and analyse. Given that patients with sepsis can deteriorate very quickly, this is too long to be used clinically. The partnership will work to develop a point-of-need test designed to indicate within about an hour which group a patient is in. If we could rapidly categorise patients in this way with an easy-to-use test, we could then run clinical trials using potential treatments.”

The Cepheid test will be based on a sample-to-answer, real-time PCR system capable of rapid, multiplexed molecular diagnostics, designed to yield results at high accuracy within minutes.

The collaboration with Oxford is part of Danaher’s Beacon programme, which funds pioneering scientific research carried out in academic settings. The ultimate objective of the programme is to develop innovative technologies and applications that can improve human health. The Beacon programme’s focus areas include genomic medicines, precision diagnostics, next generation biomanufacturing, human systems and data sciences.

Vanessa Almendro, VP, Science and Technology Innovation, Danaher, said: “We are excited for Danaher and Cepheid to collaborate with the University of Oxford on innovating new diagnostic approaches to make sepsis – one of the most life-threatening conditions – more clinically actionable. From potentially enabling precision medicine and smarter clinical trial design, to ensuring that patients are cared for in the proper settings, this work could ultimately make a difference for millions worldwide.” As well as the NIHR Oxford BRC, Professor Knight’s work has been funded by the Medical Research Council and the Wellcome Trust.

← Genetic signals that cause ankylosing spondylitis uncovered
Study highlights importance of ‘junk’ DNA in unlocking diagnosis →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre